News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Clinical

Latest News

May 19th 2017

Study Identifies Patterns of Peer Pressure With Advanced Imaging in Breast Cancer

By Surabhi Dangi-Garimella, PhD

A research study by scientists at Yale and Johns Hopkins has found that surgeons are influenced by their peers when it comes to the use of new imaging technologies.

Identifying Promising Targets to Develop Treatments for Rare Diseases

By Laura Joszt, MA

Finding Common Ground: Improving Cancer Outcomes Through Exercise

By Surabhi Dangi-Garimella, PhD

IsoPSA Test Could Reduce Overdiagnosis, Overtreatment in Prostate Cancer

By AJMC Staff

Impact of Cardiovascular Evidence on Diabetes

Latest Videos

An Overview of Atopic Dermatitis

An Overview of Atopic Dermatitis

Dr Rhonda Voskuhl Discusses Financing Early Trials of MS Therapies

Dr Rhonda Voskuhl Discusses Financing Early Trials of MS Therapies

Dr Tanuja Chitnis Details How Clinicians Are Understanding Patients' Overall Disease Course in MS

Dr Tanuja Chitnis Details How Clinicians Are Understanding Patients' Overall Disease Course in MS

Future of Therapy and Final Thoughts on Myelofibrosis

Future of Therapy and Final Thoughts on Myelofibrosis

Symptoms and Patient Progression

Symptoms and Patient Progression

Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy

Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy

Pacritinib and the Practical Implications

Pacritinib and the Practical Implications

Comparison of Ruxolitinib vs Fedratinib and Practical Implications

Comparison of Ruxolitinib vs Fedratinib and Practical Implications

Emerging Agents and Review of Fedratinib

Emerging Agents and Review of Fedratinib

Long-Term Survival and Adverse Effects With Ruxolitinib

Long-Term Survival and Adverse Effects With Ruxolitinib

More News

Understanding Cardiovascular Benefit With the LEADER Trial

May 15th 2017

GLP-1 Receptor Agonists: Initial Cardiovascular Evidence

May 15th 2017

Cardiovascular Benefit With SGLT2 Inhibition

May 15th 2017

Diabetes: Shifting the Mindset for Cardiovascular Benefits

May 15th 2017

Complexities in Diabetes Care in 2017

May 15th 2017

Results From the CANVAS Trial

May 15th 2017

Impact of EMPA-REG OUTCOME

May 15th 2017

A Historic View on CV Outcomes in Diabetes

May 15th 2017

Shared Decision-Making in Diabetes

May 15th 2017

Cost-Effectiveness and Coverage Decisions in Diabetes

May 15th 2017

Big Data Analysis and Clinical Decision Making in Diabetes

May 15th 2017

Designing Better Cardiovascular Outcomes Trials in Diabetes

May 15th 2017

Big Data and CVD Benefits of Anti-Diabetes Medications

May 15th 2017

Understanding Heart Failure in Diabetes

May 15th 2017

Cardiovascular Outcomes Trials With Anti-Diabetes Medications

May 15th 2017

SGLT2 Inhibition and CVD Outcomes in Type 2 Diabetes

May 15th 2017

Cardiovascular Outcomes With GLP-1 Receptor Agonists in Type 2 Diabetes

May 15th 2017

Impact of the EMPA-REG Study in Type 2 Diabetes

May 15th 2017

Lowering the Risk of Venous Thromboembolism With Ovarian Cancer Treatment

BySurabhi Dangi-Garimella, PhD

May 12th 2017

Twenty-five percent of patients receiving neoadjuvant chemotherapy treatment for ovarian cancer develop venous thromboembolism, according to a new study published in the journal Obstetrics & Gynecology.

Sequencing Therapies in NSCLC

May 12th 2017

Anti-Angiogenesis in NSCLC

May 12th 2017

Nondriver NSCLC: Immunotherapy and PD-L1 Expression

May 12th 2017

Immunotherapy and Chemotherapy in Second-Line NSCLC

May 12th 2017

NSCLC: Initiating Second-Line Therapy

May 12th 2017

Maintenance Following Chemotherapy in NSCLC

May 12th 2017

Trending on AJMC

Trump Childhood Vaccine Order: What It Means for Parents and Payers

CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care

CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD

OCTOPUS Trial Aims to Speed Access to Rare Sarcoma Drugs

Site of Care, TDM Still Shape AYA ALL Outcomes: Emily K. Curran, MD